UK National Health Service (NHS) staff are boycotting Palantir’s Federated Data Platform. Employees cite ethical concerns regarding the company’s U.S. defense contracts and leadership values. This resistance challenges Palantir’s standing as a trusted data partner for public health systems.
The boycott creates reputational and operational risks for Palantir’s growth in the healthcare sector. Future government contracts may depend on how the company navigates these trust and data-use issues.
Palantir stock has declined over the past month despite significant long-term gains. This controversy introduces new risks for investors as it threatens future deal flows and expansion into broader healthcare markets.